TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, announced that a poster featuring its lead therapeutic candidate, TTX-MC138, will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026 on Oct. 23 in Madrid, Spain. The presentation will highlight the latest clinical update from the Phase 1a trial evaluating TTX-MC138 in patients with advanced solid tumors. TTX-MC138 is an investigational therapeutic designed to target miR-10b, a microRNA associated with metastatic disease progression.
To view the full press release, visit https://nnw.fm/sGqsS
NOTE TO INVESTORS: The latest news and updates relating to RNAZ are available in the company’s newsroom at https://nnw.fm/RNAZ
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer